Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome

Mayo Clinic Proceedings

Volumn 76, Issue 11, 2001, Pages 1154-1162

  Elliott, M A ^a   Nichols, W L ^a  

^a MAYO CLINIC   (United States)

Author keywords

APTT = activated partial thromboplastin time; BMT = bone marrow transplantation; CP = cleaving protease; DIC = disseminated intravascular coagulation; FFP = fresh frozen plasma; HIV = human immunodeficiency virus; HUS = hemolytic uremic syndrome; LDH = lactate dehydrogenase; PT = prothrombin time; TTP = thrombotic thrombocytopenic purpura; VWF = von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CISPLATIN; CYCLOSPORIN; GEMCITABINE; GLUCOCORTICOID; MITOMYCIN; PREDNISONE; PROTEINASE; QUINIDINE; TICLOPIDINE; VON WILLEBRAND FACTOR;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME DEFICIENCY; FAMILIAL DISEASE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IDIOPATHIC DISEASE; INFECTION; ISCHEMIA; MORBIDITY; MORTALITY; PATHOGENESIS; PLASMAPHERESIS; PREGNANCY; PROTEIN DEGRADATION; REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034761325     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.11.1154     Document Type: Article

References (56)

1. Management of thrombotic thrombocytopenic purpura
2. Thrombotic thrombocytopenic purpura: Outcome in 24 patients with renal impairment treated with plasma exchange
3. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
4. Von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
5. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
6. Increasing mortality from thrombotic thrombocytopenic purpura in the United Statesanalysis of national mortality data, 1968-1991
7. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature
8. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli 0157:H7 outbreak
9. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Clinical experience in 108 patients
10. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
11. Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange
12. Studies on the pathophysiology of thrombotic thrombocytopenic purpura
13. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen
14. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
15. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
16. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
17. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
18. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura
19. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): A simplified laboratory assessment of von Willebrand factor-cleaving protease (VWF-CP) activity
20. Thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
21. Canadian Apheresis Group Laboratory abnormalities in thrombotic thrombocytopenic purpura
22. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)
23. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome
24. Thrombocytopenia due to enhanced platelet destruction by nonimmunologic mechanisms
25. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura
26. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP): Results of a randomized multicenter trial by the Italian Cooperative Group for TTP
27. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy
28. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
29. Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies
30. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
31. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus
32. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli 0157:H7 infections
33. Longterm (15-25 years) outcome of childhood hemolytic-uremic syndrome
34. A severe outbreak of Escherichia coli 0157:H7 - Associated hemorrhagic colitis in a nursing home
35. Human immunodeficiency virus infection and thrombotic microangiopathy
36. Thrombotic microangiopathies in the 1980s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic
37. Thrombotic microangiopathy during pregnancy
38. Thrombotic thrombocytopenic purpura associated with clopidogrel
39. Incidence clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting
40. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
41. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma
42. Thrombotic microangiopathy following bone marrow transplantation
43. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation
44. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplantassociated thrombotic microangiopathy
45. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura
46. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura: A 10-year experience at a single institution
47. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura
48. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura
49. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura
50. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins: Results in 17 patients
51. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura
52. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption
53. Chronic relapsing thrombotic thrombocytopenic purpura: Role of therapy with cyclosporine
54. Thrombotic thrombocytopenic purpura: Indications for and results of splenectomy
55. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpurahemolytic uremic syndrome
56. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange